Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΈ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΡ Π΅Π΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΡΠΌ Π³ΠΈΠΏΠ΅ΡΠΏΠ°ΡΠ°ΡΠΈΡΠ΅ΠΎΠ·ΠΎΠΌ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅ ΠΏΡΠΈ Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ Π½Π° ΡΠΎΠ½Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΈΡΡΠΎΡΡΠΎΠ½Π°ΡΠ°ΠΌΠΈ (Π°Π»Π΅Π½Π΄ΡΠΎΠ½Π°ΡΠΎΠΌ)
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
ΠΡΠΈ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΈΡΡΠΎΡΡΠΎΠ½Π°ΡΠ°ΠΌΠΈ (Π°Π»Π΅Π½Π΄ΡΠΎΠ½Π°ΡΠΎΠΌ) Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎ ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΠΎΡΠ΅Π½ΠΊΡ ΠΎΠ±ΡΠ΅Π³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ, ΠΊΠ°Π»ΡΡΠΈΠ΅ΠΌΠΈΠΈ, ΠΊΠ°Π»ΡΡΠΈΡΡΠΈΠΈ, Π‘ΠΠ€, ΡΡΠΎΠ²Π½Ρ ΠΠ’Π, ΠΠ, Π‘Π’Ρ ΠΈΡΡ ΠΎΠ΄Π½ΠΎ ΠΈ ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅ΡΡΡΠ° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π΄Π°Π»Π΅Π΅ 1 ΡΠ°Π· Π² Π³ΠΎΠ΄ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΡΡ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΡ ΠΎΡΠ΄Π΅Π»ΠΎΠ²: L24, Π’Π, R33o/0, Π£ΠΠ ΠΏΠΎΡΠ΅ΠΊ ΠΈ ΠΎΠΊΠΎΠ»ΠΎΡΠΈΡΠΎΠ²ΠΈΠ΄Π½ΡΡ ΠΆΠ΅Π»Π΅Π·, ΠΈΡΡ ΠΎΠ΄Π½ΠΎ, Π΄Π°Π»Π΅Π΅ 1 ΡΠ°Π· Π² Π³ΠΎΠ΄, ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΡΠΈΡ Π³ΡΡΠ΄Π½ΠΎΠ³ΠΎ ΠΈ ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠ΄Π΅Π»ΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ½ΠΎΡΠ½ΠΈΠΊΠ° ΠΈΡΡ ΠΎΠ΄Π½ΠΎ, Π΄Π°Π»Π΅Π΅ 1 ΡΠ°Π· Π² 2… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΏΠΈΡΠΎΠΊ ΠΏΡΠΈΠ½ΡΡΡΡ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ ΡΡΡ
- 1. ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΡΡΡ
- 1. 1. ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ ΡΡΡ
- 1. 2. Π¦Π΅Π»Ρ ΠΈ Π·Π°Π΄Π°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΡ
- 1. 3. ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π° ΡΡΡ
- 1. 4. ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΡΡ
- 1. 5. ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ, Π²ΡΠ½ΠΎΡΠΈΠΌΡΠ΅ Π½Π° Π·Π°ΡΠΈΡΡ ΡΡΡ
- 2. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΡΡΡ
- 2. 1. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΠΠΠ’ ΡΡΡ
- 2. 2. ΠΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΠΠΠ’ ΡΡΡ
- 2. 3. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠ°ΡΡΠΈΠ½Π° 111 ΠΠ’ ΡΡΡ
- 2. 4. ΠΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΠΠΠ’ ΡΡΡ
- 2. 5. ΠΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ· ΠΠΠΠ’ ΡΡΡ
- 2. 6. ΠΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΏΡΠΈ ΠΠΠΠ’ ΡΡΡ
- 2. 7. ΠΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ΅ΠΊ ΠΏΡΠΈ ΠΠΠΠ’ ΡΡΡ
- 2. 8. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΠΠΠ’ ΡΡΡ
- 2. 8. 1. Π₯ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΡ
- 2. 8. 2. ΠΠΎΠ½ΡΠ΅ΡΠ²Π°ΡΠΈΠ²Π½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΡ
- 2. 9. ΠΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ ΠΏΡΠΈ ΠΠΠΠ’ ΡΡΡ
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ°Π»Π°Π±ΠΎΠ»ΠΊΠΈΠ½ Π.Π., ΠΠ»Π΅Π±Π°Π½ΠΎΠ²Π° Π. Π., ΠΡΠ΅ΠΌΠΈΠ½ΡΠΊΠ°Ρ Π. Π. ΠΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. ΠΠΎΡΠΊΠ²Π°, 2002.-752 Ρ.
- Π.Π. ΠΠ΅Π»ΡΠ΅Π²Π°, Π. Π―. Π ΠΎΠΆΠΈΠ½ΡΠΊΠ°Ρ. ΠΠ½ΡΠ΅Π½ΡΠΈΠ²Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ Π³ΠΈΠΏΠ΅ΡΠΊΠ°Π»ΡΡΠΈΠ΅ΠΌΠΈΠΈ ΠΈ Π³ΠΈΠΏΠ΅ΡΠΊΠ°Π»ΡΡΠΈΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΡΠΈΠ·Π°. Consilium medicum — 2006−8(№ 9)-Ρ. 105−110/
- Π.Π. ΠΠΎΡΠΎΠ½Π΅Π½ΠΊΠΎ, Π. Π. Π‘ΡΡΠΊΠΈΠ½, ΠΠ. Π ΠΎΠΆΠΈΠ½ΡΠΊΠ°Ρ, Π. Π. ΠΠ΅Π»ΡΠ½ΠΈΡΠ΅Π½ΠΊΠΎ. ΠΠΈΠΏΠ΅ΡΠΏΠ°ΡΠ°ΡΠΈΡΠ΅ΠΎΠ· ΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠ°ΡΠΈΠΈ — 2006 № 2 — Ρ.33−41.
- ΠΠ΅Π΄ΠΎΠ² Π.Π., ΠΠ΅Π»ΡΠ½ΠΈΡΠ΅Π½ΠΊΠΎ Π. Π. Π Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΎΠ±ΠΌΠ΅Π½Π° Π²Π΅ΡΠ΅ΡΡΠ². ΠΠΎΡΠΊΠ²Π°, 2006 Π³.
- ΠΡΠ±ΡΠΎΠ²ΠΈΠ½Π° Π―.Π., Π ΠΎΠΆΠΈΠ½ΡΠΊΠ°Ρ Π .Π―., ΠΠΎΠΊΡΡΡΠ΅Π²Π° Π. Π. Ρ ΡΠΎΠ°Π²Ρ. ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ (ΠΠΠ) ΠΏΠΎΡΠ»Π΅ Ρ ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π³ΠΈΠΏΠ΅ΡΠΏΠ°ΡΠ°ΡΠΈΡΠ΅ΠΎΠ·Π° (111 111). Π’Π΅Π·ΠΈΡΡ Π΄ΠΎΠΊΠ»Π°Π΄ΠΎΠ² III Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ½Π³ΡΠ΅ΡΡΠ° ΠΏΠΎ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Ρ — 2008 — ΡΡΡ.119−120.
- Π ΠΎΠΆΠΈΠ½ΡΠΊΠ°Ρ Π.Π―. ΠΡΡΠ΅ΠΎΠΏΠ΅Π½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΏΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΈ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΡΠΉ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· (ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅): ΠΠ²ΡΠΎΡΠ΅ΡΠ΅ΡΠ°Ρ, Π΄ΠΈΡ. Π΄ΠΎΠΊΡ. ΠΌΠ΅Π΄. Π½Π°ΡΠΊ. Π., 2001.
- Π ΠΎΠΆΠΈΠ½ΡΠΊΠ°Ρ Π.Π―. Π‘ΠΎΠ»ΠΈ ΠΊΠ°Π»ΡΡΠΈΡ Π² ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ΅ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°. ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠ°ΡΠΈΠΈ — 1998 № 1. — Ρ. 43−47.
- Π―ΠΊΠΎΠ²Π»Π΅Π²Π° Π.Π‘. ΠΠ»ΠΈΠΆΠ°ΠΉΡΠΈΠ΅ ΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Ρ ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π³ΠΈΠΏΠ΅ΡΠΏΠ°ΡΠ°ΡΠΈΡΠ΅ΠΎΠ·Π°: ΠΠ²ΡΠΎΡΠ΅ΡΠ΅ΡΠ°Ρ. ΠΠΈΡ. ΠΊΠ°Π½Π΄. ΠΌΠ΅Π΄. Π½Π°ΡΠΊ. Π‘ΠΠ±., 1997.
- Ambrogini E, CetaniF, Cianferotti L, et al. Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial. J Clin Endocrinol Metab 2007 — 92(8) — pp. 3114−21.
- Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease — a review. European Heart Journal 2004 — 25(20) — pp. 1776−1787.
- Ayturk S, Gursoy A, Bascil Tutuncu N, et al. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2006 Nov — 91(11) -pp. 4260−3.
- Bilezikian JP. Bone strength in primary hyperparathyroidism. Osteoporos Int -2003 14 (5)-pp. SI 13−5.
- Bilezikian JP, Brandi ML, Rubin M & Silverberg S J. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. Journal of Internal Medicine 2005 — 257(7) — pp. 6— 17
- Bilezikian JP, Potts JT, Fuleihan GE-H, et al. Summary statement from a workshop on asymptomatic primary hyperthyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002 -87(6) — pp. 5353−61.
- Bilezikian JP, Rubin M & Silverberg SJ. Primary hyperparathyroidism: diagnosis, evaluation, and treatment. Curr Opin in Endocrinol and Diabetes -2004−11(3)-pp. 345−52.
- Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009 Feb -94(2) -pp. 335−9.
- Bischoff-Ferrari HA. Extra-skeletal effects of vitamin D. Curr Opin in Endocrinol and Diabetes 2005 — 2(2) — pp. 464—70.
- Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation compared to parathyroidectomy for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab — 2007 — 92(5) — pp. 1687−92.
- Brown GG, Preisman RC, Kleerekoper M. Neurobehavioral symptoms in mild primary hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Hospital Med J. — 1987 -35(3) -pp. 211−215.
- Burney RE, Jones KR, Christy B, et al. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery — 1999 125 (5)-pp. 608−14.
- Caufriez A. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. Ann Endocrinol (Paris) — 2007 — 68(4) — pp. 241−50.
- Chan AK, Duh QY, Katz MH, et al. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann.Surg. 1995 — 222(2) — pp. 402−12.
- Charhon SA, Edouard CM, Arlot ME, et al. Effects of parathyroid hormone on remodeling of iliac trabecular bone packets in patients with primary hyperparathyroidism. Clin Orthop RelatRes 1982 — 162(2) — pp. 255−63.
- Chiang CY, Andrewest DC, Anderson D, et al. A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clin Endocrinol — 2005- 62(7) pp. 99—104.
- Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003 — 88(5) — pp. 581−7.
- Christiansen P, Steiniche T, Vesterby A, et al. Primary hyperparathyroidism: iliac crest trabecular bone volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone — 1992 13(4) — pp. 41— 9.
- Coker L, Rone K, Cantley L, et al. Primary Hyperparathyroidism, Cognition, and Health-Related Quality of Life. Ann Surg 2005 — 242(5) — pp. 642−650.
- D’Angelo A, Lodetti MG, Giannini S, et al. Hyperparathyroidism: cause or consequence of recurrent calcium nefrolithiasis. Miner Electrolyte Metab — 1992- 18(3)-pp. 359−64.
- Dempster DW, Caldwell NJ, Goldstein SA, et al. Three dimensional assessment of trabecular architecture in mild primary hyperparathyroidism. J Bone Miner Res 2002- 17 Suppl 1. — pp. 1173a.
- Dempster DW, Parisien M, Silverberg SJ, et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999 — 84(3) — pp. 1562−6.
- Ellis G, Spirtos G, Polsky F. Primary hyperparathyroidism and coexisting nephrogenic diabetes insipidus: rapid postoperative correction. South Med J-1991−84(8)-pp. 1019−22.
- Fitz TE, Hallman BL. Mental changes associated with hyperparathyroidism. Arch Intern Med 1952 — 89(2) — pp. 547−551.
- Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000 — 11(6) — pp. S55−65.
- De Geronimo S, Romagnoli E, Diacinti D, et al. The risk of fractures in postmenopausal women with primary hyperparathyroidism. European Journal of Endocrinology 2006 — 155(3) — pp. 415−20.
- Gianotti L, Tassone F, Cesario F, et al. A Slight Decrease in Renal Function Further Impairs Bone Mineral Density in Primary Hyperparathyroidism. J Clin Endocrinol Metab 2006 — 91(8) — pp. 3011−6.
- Goyal A, Chumber S, Tandon N, et al. Neuropsychiatrie manifestations in patients of primary hyperthyroidism and outcome following surgery. Indian J Med Sei. 2001 — 55(4) — pp. 677−86.
- Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 1996 — 125(7) — pp. 360−8.
- Guo CY, Thomas WE, al-Dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996 — 81(10) — pp. 348 791.
- Grey AB, Evans MC, Stapleton JP, Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Intern Med -1994 121(10) — pp. 745−9.
- Hamdy NA, Gray RD, McCloskey E, et al. Clodronate in the medical management of hyperparathyroidism. Bone — 1987 (Suppl 1) — pp. S69-S77.
- Harrison BJ, Wheeler MH. Asymptomatic primary hyperparathyroidism. World J Surg. 1991 — 15(1) — pp. 724−729.
- Hassani S, Braunstein GD, Seibel MJ, et al. Alendronate therapy of primary hyperparathyroidism. Endocrinologist — 2001 — 11(5) — pp. 459−64.
- Hedback G, Oden A. Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Invest -1998−28(5)-pp.l011−1018.
- Horiuchi T, Onouchi T, Inoue J et al. A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology — 2002 — 48(2) — pp. 103−8.
- Hsu CY, Cummings SR, McCulloch CE, Chertow GM Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int -2002−61(3)-pp. 1814−20.
- Jansson S, Morgan E. Biochemical Effects from Treatment with Bisphosphonate and Surgery in Patients with Primary Hyperparathyroidism. World J Surg. 2004 — 28(12) — pp. 1293−7.
- Jones DB, Jones JH, Lloyd HJ, et al. Changes in blood pressure and renal function after parathyroidectomy in primary hyperparathyroidism. Postgraduate Med J- 1983 59(3) — pp. 350−3.
- Kaji H, Yamauchi M, Chihara K & Sugimoto T. The threshold of bone mineral density for vertebral fractures in female patients with primary hyperparathyroidism. European Journal of Endocrinology 2005 — 153(7) — pp. 373−8.
- Kashitani T, Makino H, Nagake Y, et al. Two cases of hypercalcemic nephropathy associated with primary hyperparathyroidism. Nippon Jinzo Gakkai Shi. 1993 — 35(10) — pp. 1189−94.
- Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ- 2000 163 (2) — pp. 184−7.
- Khan A, Bilezikian J, Kung A et al. Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab 2004 — 89(7) -pp.3319−25.
- Khosla S, Melton LJ, III, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999 — 14(3)-pp. 1700−07.
- Kristoffersson A, Backman C, Granqvist K & Jarhult J. Pre- and postoperative evaluation of renal function with five different tests in patients with primary hyperparathyroidism. JInt Med 1990 — 227(3) — pp. 317—24.
- Larsson K, Ljunghall S, Krusemo UB, et al. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. Journal of Internal Medicine 1993 — 234(3) -pp. 585−93.
- Marx S, Attie M. Maximal urine-concentrating ability: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. J Clin Endocrinol Metab 1981 — 52(4)-pp.736−40.
- Mittendorf EA, McHenry CR. Persistent parathyroid hormone elevation following curative parathyroidectomy for primary hyperparathyroidism. Arch. Otolaryngol. Head Neck Surg. 2002 — 128(2) — pp. 275−9.
- Mollerup CL, Lindewald H. The natural history of renal stone disease after successful parathyroidectomy. World J Surg- 1999 — 23(2) — pp. 173−6.
- Mollerup C, Vestergaard P, Frakjaer V, et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ- 2002 325(5) — pp. 807.
- Mosekilde L, Charles P, Lindegreen P. Determinants for serum 1,25-dihydroxycholecalciferol in primary hyperparathyroidism. Bone Miner -1989−5(2)-pp. 279−90.
- Nakaoka D, Sugimoto T, Kobayashi T et al. Prediction of Bone Mass Change after Parathyroidectomy in Patients with Primary Hyperparathyroidism. J Clin Endocrinol Metab 2000 — 85(5) — pp. 1901−07.
- NIH Consensus Development Panel Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. Ann Intern Med — 1991 114 (7) — pp. 593−7.
- Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002 — 17(1) — pp. 1741−3.
- Parisien M, Mellish RW, Silverberg SJ, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular and strut analysis. J Bone Miner Res 1992 — 7(1) — pp. 913−20.
- Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone. J Clin Endocrinol Metab 1990 — 70(1) — pp. 930−8.
- Parker C, Blackwell P, Fairbairn K, Hosking DJ. Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study. J Clin Endocrinol Metab 2002 — 87(10) -pp.4482−9.
- Pasieka JL, Parsons LL, Demeure MJ, et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg — 2002 26(1) -pp. 942−9.
- Peacock M, Bilezikian J, Klassen P, et al. Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism. J Clin Endocrinol Metab 2005 — 90(1) — pp. 135−41.
- Pfeilschifter J, Siegrist E, Wiister C, et al. Serum levels of intact parathyroid hormone and alkaline phosphatase correlate with cortical and trabecular bone loss in primary hyperparathyroidism. Acta Endocrinol (Copenh) 1992 -127(4)-pp. 319−23.
- Posen S, Clifiton-Bligh P, Reeve TS, et al. Is parathyroidectomy of benefit in primary hyperparathyroidism? O J Med 1985 — 54(215) — pp. 241 -51.
- Quiros RM, Alef MJ, Wilhelm SM, et al. Health-related quality of life in hyperparathyroidism measurably improves after parathyroidectomy. Surgery 2003 — 134(4) — pp. 675−81.
- Rao DS, Honasoge M, Divine GW, et. al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000 — 85(3)-pp. 1054−8.
- Rao D, Phillips E, Divine G, B. Talpos G. Randomized Controlled Clinical
- Trial of Surgery Versus No Surgery in Patients with Mild Asymptomatic145
- Primary Hyperparathyroidism. J Clin Endocrinol Metab 2004- 89(11) — pp. 5415−22.
- Roman SA, Sosa JA, Mayes L, et al. Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery 2005 — 138(3) — pp. 1121−8.
- Rossini M, Gatti D, Isaia G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001 — 16(2) — pp. 113−9.
- Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008 — 93(3) — pp. 3462−70.
- Rubin MR, Cosman F, Lindsay R & Bilezikian JP. The anabolic effects of parathyroid hormone. Osteoporos Int 2002 — 13(1) — pp. 267−77.
- Scillitani A, Guarnieri V, Battista C, et al. Primary hyperparathyroidism and the presence of kidney stones are associated with different haplotypes of the calcium-sensing receptor. J Clin Endocrinol Metab 2007 — 92(1) — pp. 27 783.
- Sheldon DG, Lee FT, Neil NJ, et al. Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg — 2002- 137(3)-pp. 1022−8.
- Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab — 1995 80(3) — pp. 723−8.
- Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989 — 4 (3) — pp. 283—91.
- Silverberg S J, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. American Journal of Medicine 1999 — 107 (2) — pp.561−567.
- Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med- 1999−341(2)-pp. 1249−55.
- Silverberg SJ, Shane E, Jacobs TP, et al. Nefrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990 — 89(1) — pp. 327−34.
- Silverberg SJ, Brown I, Bilezikian JP. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med 2002 — 113(8) — pp. 681−4.
- Siminoski K, Jiang G, Adachi JD, et. al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int- 2005 16(4) — pp. 403−10.
- Soreide JA, Heerden JA, Grant CS, et al. Characteristics of patients surgically treated for primary hyperparathyroidism with and without renal stones. Surgery- 1996 -120(3) pp. 1033−7.
- Sywak MS, Knowlton ST, Pasieka JL, et al. Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity and surgical outcome in patients with primary hyperparathyroidism? Surgery 2002 — 132 (2) — pp. 1013−20.
- Talpos GB, Bobe HG, Kleerekoper M, et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects of the SF-36 health survey. Surgery — 2000 -128(3) — pp. 1013−21.
- VanderWalde L, Liu I, O’Connell T, Haigh P. The Effect of Parathyroidectomy on Bone Fracture Risk in Patients With Primary Hyperparathyroidism. Arch Surg — 2006 — 141 (1) pp. 885−91.
- Vestergaard P, Mollerup CL, Frokjaer VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ — 2000 321(2) — pp. 598−602.
- Vestergaard P, Mosekilde L. Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study. J Int Med 2004 — 255 (1)-pp. 108−14.
- Vezzoli G, Tanini A, Ferrucci L, et al. Influence of the calcium-sensing receptor gene on urinary calcium excretion in stone forming patients. J Am Soc Nephrol 2002 — 13 (10) — pp. 2517−23.
- Vogel M, Hahn M, Delling G. 1995 Trabecular structure in patients with primary hyperparathyroidism. Virchows Arch 426 (2) — pp. 127—134.
- Weber T, Keller M, Hense I, et al. Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism. World J Surg — 2007 — 31 (6) — pp. 1202−9.
- Wermers RA, Khosla S, Atkinson EJ, et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965−1992. Ann Intern Med- 1997−126 (6) pp. 433−40.
- Wilhelm S, Lee J, Prinz RA. Major depression due to primary hyperparathyroidism: a frequent and correctable disorder. Am Surgeon — 2004−70 (2)-pp. 175−80.
- Wilson RJ, Sudhaker R, Ellis B, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Annals of Internal Medicine 1988 — 109(12) — pp. 959−62.
- Yamashita H, Noguchi S, Uchino S, et al. Influence of renal function on clinico-pathological features of primary hyperparathyroidism. Eur J Endocrinol-2003- 148(6)-pp. 597−602.